LBRX (LB Pharmaceuticals) Piotroski F-Score: N/A (As of Jun. 29, 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.15
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LB Pharmaceuticals has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for LB Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of LB Pharmaceuticals was 3. The lowest was 3. And the median was 3.

LB Pharmaceuticals  (NAS:LBRX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


LB Pharmaceuticals Piotroski F-Score Related Terms


LB Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Piotroski F-Score Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A N/A 3.00

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 3.00 N/A

LBRX vs MRVI, SLDB, JANX: Piotroski F-Score Comparison

For the Biotechnology subindustry, LB Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LB Pharmaceuticals Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LB Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where LB Pharmaceuticals's Piotroski F-Score falls into.


LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -4.871 + -3.556 + -11.472 + -19.054 = $-38.95 Mil.
Cash Flow from Operations was -5.604 + -3.373 + -18.103 + -23.29 = $-50.37 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(0 + 19.248 + 320.746 + 312.934 + 393.482) / 5 = $261.6025 Mil.
Total Assets at the begining of this year (Mar25) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $2.74 Mil.
Total Current Assets was $389.07 Mil.
Total Current Liabilities was $10.91 Mil.
Net Income was -27.696 + -14.181 + -5.071 + -5.306 = $-52.25 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(74.26 + 0 + 0 + 33.534 + 0) / 5 = $53.897 Mil.
Total Assets at the begining of last year (Mar24) was $74.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.00 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LB Pharmaceuticals's current Net Income (TTM) was -38.95. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LB Pharmaceuticals's current Cash Flow from Operations (TTM) was -50.37. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-38.953/0
=

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-52.254/74.26
=-0.70366281

LB Pharmaceuticals's return on assets of this year was . LB Pharmaceuticals's return on assets of last year was -0.70366281. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

LB Pharmaceuticals's current Net Income (TTM) was -38.95. LB Pharmaceuticals's current Cash Flow from Operations (TTM) was -50.37. ==> -50.37 <= -38.95 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=2.74/261.6025
=0.01047391

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/53.897
=0

LB Pharmaceuticals's gearing of this year was 0.01047391. LB Pharmaceuticals's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=389.074/10.906
=35.67522465

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=0/0
=

LB Pharmaceuticals's current ratio of this year was 35.67522465. LB Pharmaceuticals's current ratio of last year was . ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

LB Pharmaceuticals's number of shares in issue this year was 28.242. LB Pharmaceuticals's number of shares in issue last year was 22.443. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

LB Pharmaceuticals's gross margin of this year was . LB Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/74.26
=0

LB Pharmaceuticals's asset turnover of this year was . LB Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+1+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LB Pharmaceuticals has an F-score of 1. It is a bad or low score, which usually implies poor business operation.


LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.15
Price